

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 87787

Title: Gut-targeted therapies for Type 2 diabetes mellitus: A review

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02461627 Position: Peer Reviewer Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: United Arab Emirates

Author's Country/Territory: China

Manuscript submission date: 2023-08-27

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-08-27 08:06

Reviewer performed review: 2023-08-27 16:18

Review time: 8 Hours

	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No creativity or innovation



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [] Grade B: Minor language polishing [Y] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Re-review	[Y] Yes [] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The manuscript entitled "Gut-targeted therapies for T2DM: A review" authored by Xu and colleagues reviewed Type 2 diabetes mellitus (T2DM) as a chronic metabolic disorder that is characterized by hyperglycemia and insulin resistance. Authors referred to the current treatments for T2DM include lifestyle modifications, oral antidiabetic agents, and insulin therapy and acknowledged that therapies may carry side effects and fail to achieve optimal glycemic control in some patients. They then discussed gut-targeted therapies, such as probiotics and fecal microbiota transplantation (FMT) that have shown potential for improving glycemic control and insulin sensitivity in T2DM patients. They also showed that NIH Stimulating Peripheral Activity to Relieve Conditions (SPARC) program research initiative was aimed at developing new therapies for a variety of health conditions, including T2DM. Briefly, SPARC program focuses on using electrical stimulation to activate peripheral nerves and organs, in order to regulate glucose levels in the body. Authors then concluded that further research is required to determine the optimal dose, duration, and safety of new therapies. It is essential to shed more light on the molecular mechanisms involved in developing diabetes. The following



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

studies should be integrated to serve such purpose: a http://dx.doi.org/10.4236/jdm.2011.13006, PMID: 29959408, PMID: 17151320. The following are important to be fully addressed: What time range of publication did this review article cover, what keywords did the search for literature include, what were the inclusion criteria, how many studies did the search find and how many were primary research vs review articles, of those, how many were selected for evaluation in this study, and finally what criteria were used for selecting the articles that were reviewed (was it the subject of the study, its novelty or both). Other comments Careful proofreading is required. • Abbreviation list should be added. • A conclusion figure should be added to summarize the take-home message of this work.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 87787

Title: Gut-targeted therapies for Type 2 diabetes mellitus: A review

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02461627 Position: Peer Reviewer Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: United Arab Emirates

Author's Country/Territory: China

Manuscript submission date: 2023-08-27

Reviewer chosen by: Ji-Hong Liu

Reviewer accepted review: 2023-11-27 05:36

Reviewer performed review: 2023-11-27 05:41

Review time: 1 Hour

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

none